269 related articles for article (PubMed ID: 20102012)
41. Highlights in myelodysplastic syndromes from the 2020 American Society of Clinical Oncology Annual Meeting and the 25th European Hematology Association Congress.
Clin Adv Hematol Oncol; 2020 Sep; 18 Suppl 14(9):1-24. PubMed ID: 33843880
[No Abstract] [Full Text] [Related]
42. [Quantitative-kinetic aspects of granulocytic resistance to infection in hematologic systemic diseases with reference to antineoplastic chemotherapy].
Sommer S
Z Arztl Fortbild (Jena); 1988; 82(11):513-5. PubMed ID: 3176536
[No Abstract] [Full Text] [Related]
43. Highlights in myelodysplastic syndromes from the 2020 American Society of Clinical Oncology Annual Meeting and the 25th European Hematology Association Congress: commentary.
Garcia-Manero G
Clin Adv Hematol Oncol; 2020 Sep; 18 Suppl 14(9):20-23. PubMed ID: 33843881
[No Abstract] [Full Text] [Related]
44. Targeted therapy for hematologic malignancies.
Kuriakose P
Cancer Control; 2005 Apr; 12(2):82-90. PubMed ID: 15855891
[TBL] [Abstract][Full Text] [Related]
45. Therapeutic epigenetics: an emerging clinical approach to hematologic malignancies.
Clin Adv Hematol Oncol; 2005 Mar; 3(3 Suppl 1):1-10; quiz 11-2. PubMed ID: 21438190
[No Abstract] [Full Text] [Related]
46. 49th Annual Meeting of the American Society of Hematology, Atlanta, GA; December 8-11, 2007.
Clin Lymphoma Myeloma; 2008 Apr; 8(2):77-86. PubMed ID: 18564453
[No Abstract] [Full Text] [Related]
47. Leukemias and myeloma.
Wiernik PH
Cancer Chemother Biol Response Modif; 1994; 15():391-412. PubMed ID: 7779590
[No Abstract] [Full Text] [Related]
48. Leukemias and myeloma.
Wiernik PH
Cancer Chemother Biol Response Modif; 1988; 10():129-47. PubMed ID: 3079381
[No Abstract] [Full Text] [Related]
49. Azacitidine-eligibility in higher-risk myelodysplastic syndromes and chronic myelomonocytic leukaemia: a registry-based study.
Durairaj S; Keenan N; Hyslop A; Groves MJ; Bowen DT; Tauro S
Br J Haematol; 2013 Apr; 161(2):280-2. PubMed ID: 23294041
[No Abstract] [Full Text] [Related]
50. [IMiDs in hematology].
Wémeau M; Gauthier J; Leleu X; Yakoub-Agha I
Bull Cancer; 2011 Aug; 98(8):879-87. PubMed ID: 21827980
[TBL] [Abstract][Full Text] [Related]
51. American Society of Hematology--50th Annual Meeting and Exposition--Part 1.
Scattereggia J; Millar E
IDrugs; 2009 Feb; 12(2):63-5. PubMed ID: 19216123
[No Abstract] [Full Text] [Related]
52. Novel and Expanded Oncology Drug Approvals of 2016-PART 2: New Options in the Management of Hematologic Malignancies.
Knepper TC; Saller J; Walko CM
Oncology (Williston Park); 2017 Feb; 31(2):138-46. PubMed ID: 28205194
[TBL] [Abstract][Full Text] [Related]
53. Leukemia.
McKenna SJ
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2000 Feb; 89(2):137-9. PubMed ID: 10673646
[No Abstract] [Full Text] [Related]
54. Emerging antibody-drug conjugates for treating lymphoid malignancies.
Wolska-Washer A; Robak P; Smolewski P; Robak T
Expert Opin Emerg Drugs; 2017 Sep; 22(3):259-273. PubMed ID: 28792782
[TBL] [Abstract][Full Text] [Related]
55. [Proteasome inhibitors].
Hatake K; Mishima Y; Terui Y
Gan To Kagaku Ryoho; 2004 Jul; 31(7):999-1002. PubMed ID: 15272575
[TBL] [Abstract][Full Text] [Related]
56. [The standard treatments for patients with hematological malignancies in Japan].
Ishizawa K
Gan To Kagaku Ryoho; 2007 May; 34(5):709-12. PubMed ID: 17496442
[TBL] [Abstract][Full Text] [Related]
57. 42nd Annual Meeting of American Society of Hematology. San Francisco, CA. December 1-5, 2000.
D'Orazio AI; Gambill BD
Clin Lymphoma; 2001 Mar; 1(4):251-6. PubMed ID: 11715982
[No Abstract] [Full Text] [Related]
58. Proposals for standardized protocols for cytogenetic analyses of acute leukemias, chronic lymphocytic leukemia, chronic myeloid leukemia, chronic myeloproliferative disorders, and myelodysplastic syndromes.
Haferlach C; Rieder H; Lillington DM; Dastugue N; Hagemeijer A; Harbott J; Stilgenbauer S; Knuutila S; Johansson B; Fonatsch C
Genes Chromosomes Cancer; 2007 May; 46(5):494-9. PubMed ID: 17311250
[TBL] [Abstract][Full Text] [Related]
59. [Double cancer in elderly patients with hematologic malignancies].
Niitsu N; Umeda M
Nihon Ronen Igakkai Zasshi; 1996 Apr; 33(4):269-72. PubMed ID: 8752714
[TBL] [Abstract][Full Text] [Related]
60. Dasatinib dosing strategies in Philadelphia chromosome-positive leukemia.
Wong SF
J Oncol Pharm Pract; 2009 Mar; 15(1):17-27. PubMed ID: 18753186
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
